Yurii Saroz

Yurii Saroz

Auto-generated profile, based on publicly available information

Yurii Saroz

Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 1142 Auckland, New Zealand

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
YSYurii Saroz
Yurii Saroz
DKDan T. Kho
Dan T. Kho
MGMichelle Glass
Michelle Glass
EGEuan Scott Graham
Euan Scott Graham
Natasha GrimseyNatasha Grimsey
Natasha Grimsey
Cannabinoid receptor 2 (CB2) is a promising therapeutic target for immunological modulation. There is, however, a deficit of knowledge regarding CB2 signaling and function in human primary immunocompetent cells. We applied an experimental paradigm which closely models the in situ state of human primary leukocytes (PBMC; peripheral blood mononuclear cells) to characterize activation of a number of signaling pathways in response to a CB2-selective ligand (HU308). We observed a “lag” phase of unchanged cAMP concentration prior to development of classically expected Gαi-mediated inhibition of cAMP synthesis. Application of G protein inhibitors revealed that this apparent lag was a result of counteraction of Gαi effects by concurrent Gαs activation. Monitoring downstream signaling events showed that activation of p38 was mediated by Gαi, whereas ERK1/2 and Akt phosphorylation were mediated by Gαi-coupled βγ. Activation of CREB integrated multiple components; Gαs and βγ mediated ∼85% of the response, while ∼15% was attributed to Gαi. Responses to HU308 had an important functional outcome—secretion of interleukins 6 (IL-6) and 10 (IL-10). IL-2, IL-4, IL-12, IL-13, IL-17A, MIP-1α, and TNF-α were unaffected. IL-6/IL-10 induction had a similar G protein coupling profile to CREB activation. All response potencies were consistent with that expected for HU308 acting via CB2. Additionally, signaling and functional effects were completely blocked by a CB2-selective inverse agonist, giving additional evidence for CB2 involvement. This work expands the current paradigm regarding cannabinoid immunomodulation and reinforces the potential utility of CB2 ligands as immunomodulatory therapeutics.

9 September 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RSRoman Clà Sarott
Roman Clà Sarott
MWMatthias V. Westphal
Matthias V. Westphal
PPPatrick Pfaff
Patrick Pfaff
CKClaudia Korn
Claudia Korn
DSDavid A. Sykes
David A. Sykes
ECErick Moran Carreira
Erick Moran Carreira

20 November 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
COCaitlin R. M. Oyagawa
Caitlin R. M. Oyagawa
SHSara M. de la Harpe
Sara M. de la Harpe
YSYurii Saroz
Yurii Saroz
MGMichelle Glass
Michelle Glass
AVAndrea J. Vernall
Andrea J. Vernall
Natasha GrimseyNatasha Grimsey
Natasha Grimsey
Cannabinoid receptor 2 (CB2) is predominantly distributed in immune tissues and cells and is a promising therapeutic target for modulating inflammation. In this study we designed and synthesised a series of 2,4,6-trisubstituted 1,3,5-triazines with piperazinylalkyl or 1,2-diethoxyethane (PEG2) chains as CB2 agonists, all of which were predicted to be considerably more polar than typical cannabinoid ligands. In this series, we found that triazines containing an adamantanyl group were conducive to CB2 binding whereas those with a cyclopentyl group were not. Although the covalent attachment of a PEG2 linker to the adamantyl triazines resulted in a decrease in binding affinity, some of the ligands produced very interesting hCB2 signalling profiles. Six compounds with notable hCB2 orthosteric binding were functionally characterised in three pathways; internalisation, cyclic adenosine monophosphate (cAMP) and ERK phosphorylation (pERK). These were predominantly confirmed to be hCB2 agonists, and upon comparison to a reference ligand (CP 55,940), four compounds exhibited signalling bias. Triazines 14 (UOSD017) and 15 were biased towards internalisation over cAMP and pERK, and 7 was biased away from pERK activation relative to cAMP and internalisation. Intriguingly, the triazine with an amino-PEG2-piperazinyl linker (13 [UOSD008]) was identified to be a mixed agonist/inverse agonist, exhibiting apparent neutral antagonism in the internalisation pathway, transient inverse agonism in the cAMP pathway and weak partial agonism in the pERK pathway. Both the cAMP and pERK signalling were pertussis toxin (PTX) sensitive, implying that 13 is acting as both a weak agonist and inverse agonist at CB2 via Gαi/o. Compound 10 (UOSD015) acted as a balanced high intrinsic efficacy agonist with the potential to produce greater hCB2-mediated efficacy than reference ligand CP 55,940. As 10 includes a Boc-protected PEG2 moiety it is also a promising candidate for further modification, for example with a secondary reporter or fluorophore. The highest affinity compound in this set of relatively polar hCB2 ligands was compound 16, which acted as a slightly partial balanced agonist in comparison with CP 55,940. The ligands characterised here may therefore exhibit unique functional properties in vivo and have the potential to be valuable in the future development of CB2-directed therapeutics.

12 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYurii Saroz
Yurii Saroz
DKDan Kho
Dan Kho
MGMichelle Glass
Michelle Glass
SGScott Graham
Scott Graham
Natasha GrimseyNatasha Grimsey
Natasha Grimsey
Cannabinoid receptor 2 (CB 2 ) is a promising therapeutic target for immunological modulation. There is, however, a deficit of knowledge regarding CB 2 signaling and function in human primary immunocompetent cells. We applied an experimental paradigm which closely models the in situ state of human primary leukocytes (PBMC; peripheral blood mononuclear cells) to characterize activation of a number of signaling pathways in response to a CB 2 -selective ligand (HU308). We observed a “lag” phase of unchanged cAMP concentration prior to development of classically-expected Gα i -mediated inhibition of cAMP synthesis. Application of G protein inhibitors revealed that this apparent lag was a result of counteraction of Gα i effects by concurrent Gα s activation. Monitoring downstream signaling events, activation of p38 was mediated by Gα i whereas ERK1/2 and Akt phosphorylation were mediated by Gα i -coupled βγ. Activation of CREB integrated multiple components; Gα s and βγ mediated ∼85% of the response, while ∼15% was attributed to Gα i . Responses to HU308 had an important functional outcome – secretion of interleukins 6 (IL-6) and 10 (IL-10). IL-2, IL-4, IL-12, IL-13, IL-17A, MIP-1α, and TNF-α were unaffected. IL-6/IL-10 induction had a similar G protein coupling profile to CREB activation. All response potencies were consistent with that expected for HU308 acting via CB 2 . Additionally, signaling and functional effects were completely blocked by a CB 2 -selective inverse agonist, giving additional evidence for CB 2 involvement. This work expands the current paradigm regarding cannabinoid immunomodulation and reinforces the potential utility of CB 2 ligands as immunomodulatory therapeutics. Significance statement: Cannabinoid receptor 2 (CB2) is a G protein-coupled receptor which plays a complex role in immunomodulation and is a promising target in a range of disorders with immune system involvement. However, to date the majority of the studies in this field have been performed on cell lines, rodent models, or stimulated primary cells. Here we provide a detailed account of CB2-mediated signaling in primary human immune cells under conditions which closely mimic their in vivo state. We reveal a complex signaling system involving an unprecedented CB2 signaling pathway and leading to immunomodulatory functional outcomes. This work provides not only a critical foundation impacting CB2-targeted drug discovery, but reveals important wider considerations for GPCR signaling studies and model validity. Table of Contents Summary Figure: